Targeting peripheral 5-HT(2A)R enhances antitumor immunity in colorectal cancer.
A gut-targeted serotonin receptor drug helps immune cells fight colorectal cancer without affecting the brain, potentially improving treatment response in patients with hard-to-treat tumors.
Peripheral serotonin receptor 5-HT2AR on enteric glial cells regulates antitumor immunity in colorectal cancer; the non-brain-penetrant agonist IHCH-8110 enhances CD8+ T cell recruitment and effector polarization within tumors, converting immune-cold CRC to an immunotherapy-responsive state. IHCH-8110 dramatically improves PD-1 blockade efficacy in preclinical CRC models while avoiding psychedelic CNS effects.
What the study was
- Study design
- original_research
- Population
- Colorectal cancer preclinical models
- Category
- Immunotherapy
- Maturity
- Exploratory
- Journal
- Cell
Why it surfaced
Cell publication identifying novel peripheral 5-HT2AR → enteric glial → CXCL10/IL-18 → CD8+ T cell recruitment axis in CRC; IHCH-8110 as brain-penetrant-avoidant agonist enabling immunotherapy sensitization without CNS effects; strong PD-1 combination data; paradigm-shifting neuro-oncology intersection with immediate translational relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.